Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series [Yahoo! Finance]
Regulus Therapeutics Inc. (RGLS)
Last regulus therapeutics inc. earnings: 3/12 04:37 pm
Check Earnings Report
US:NASDAQ Investor Relations:
regulusrx.com/investors
Company Research
Source: Yahoo! Finance
of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024 , at 1:00 p.m. ET The live event will be available here and a replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date. About Regulus Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its c
Show less
Read more
Impact Snapshot
Event Time:
RGLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGLS alerts
High impacting Regulus Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
RGLS
News
- Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerPR Newswire
- Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates [Yahoo! Finance]Yahoo! Finance
- Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesPR Newswire
- Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]Yahoo! Finance
RGLS
Earnings
- 5/9/24 - Miss
RGLS
Sec Filings
- 5/9/24 - Form 424B5
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- RGLS's page on the SEC website